AstraZeneca PLC

NYSE:AZN

Drug Manufacturers - General

Healthcare
$178.76 -1.71%

-$3.04 today

Market cap
$277.23B
Beta
0.21
P/E (TTM)
25.7
EPS (TTM)
$6.75
Dividend yield
1.80%
52W Low $137.22High $212.71

Volume 2.54M

Average 1.96M

AZN Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

AstraZeneca PLCNYSE: AZN

Change in Working Capital · Q3 FY2026 · quarter ended Sep 2026

Change in working capital turns negative

Q3 FY2026 change in working capital was -$288.26M, compared with $835M a year earlier. Trailing-twelve-month change in working capital was -$2.95B.

Context

  • Change in working capital amounted to 2.0% of revenue in FY2025, up 0.3 pp from a year earlier.
  • Change in working capital increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly change in working capital holds near -$288.26M or moves back toward the trailing-twelve-month quarterly average of -$737.36M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$288.26M-33.5% QoQ
Last fiscal yearDec 2025
-$1.16B+30.2% YoY
LTMSep 2026
-$2.95B+931.3% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-134.5%——
1 year+30.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
(1.16B) USD
Year-over-year change
-30.2%

Change in Working Capital vs competitors

How AZN compares with its peers on the latest reported figures

  • Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +931.3% is the highest of 10, against a peer median of -51.8%.
  • Change in working capital amounts to 4.7% of revenue for AZN, versus a peer median of 3.6%.
AZN Competitors
Change in Working Capital for AZN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JNJJohnson & JohnsonLTM Sep 2026$11.68B USD-1563.0%+46.9%11.8%
LLYEli Lilly and CompanyLTM Jun 2026$4.8B USD-38.9%+2062.8%6.0%
NVONovo Nordisk A/SLTM Jun 2026DKK 4.5B DKK-51.8%—1.4%
ABBVAbbVie Inc.LTM Jun 2026$3.86B USD+38.5%+109.2%6.0%
AZNAstraZeneca PLCLTM Sep 2026$2.95B USD+931.3%—4.7%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$2.23B USD-297.4%-41.1%4.5%
NVSNovartis AGLTM Jun 2026$2.03B USD+308.2%+56.9%3.6%
PFEPfizer Inc.LTM Jun 2026$1.99B USD-35.7%+6.3%3.1%
MRKMerck & Co., Inc.LTM Jun 2026$1.25B USD-76.1%+35.9%1.9%
AMGNAmgen Inc.LTM Jun 2026$516M USD-144.5%+39.2%1.4%
Peer median (excluding AZN) —-51.8%+43.1%3.6%

Competitors are the stored peer set for AZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(265M)2.5B6.9B8.69B10.23B
Depreciation & Amortization4.1B5.25B4.93B5.07B5.73B
Deferred Income Tax(615M)(619M)000
Stock-Based Compensation615M619M579M00
Change in Working Capital2.02B3.76B300M(893M)(1.16B)
Accounts Receivables(961M)(1.35B)(1.43B)(1.62B)0
Inventory1.58B3.94B(669M)(131M)0
Accounts Payables961M1.35B1.43B00
Other Working Capital444M(184M)969M862M(1.16B)
Other Non-Cash Items105M(1.7B)(2.37B)(1B)(220.71M)
Operating Cash Flow5.96B9.81B10.35B11.86B14.58B
Capital Expenditures(2.2B)(2.57B)(3.78B)(4.59B)(5.91B)
Acquisitions (Net)(9.43B)(1.06B)(1.18B)(3.93B)(1.24B)
Purchases of Investments(184M)(159M)(136M)(96M)(229M)
Sales of Investments105M42M129M108M131M
Other Investing Activities654M789M(1.52B)(2.14B)(2.66B)
Investing Cash Flow(11.06B)(2.96B)(4.06B)(7.98B)(6.81B)
Debt Repayment7.89B(1.2B)(965M)1.81B(1.65B)
Common Stock Issued29M29M33M(43M)(481M)
Common Stock Repurchased00000
Dividends Paid(3.86B)(4.36B)(4.48B)(4.63B)(4.97B)
Other Financing Activities(418M)(1.29B)(1.15B)(1.13B)(442M)
Financing Cash Flow3.65B(6.82B)(6.57B)(4B)(7.54B)
Effect of Forex Changes(62M)(80M)(60M)(93M)46M
Net Change in Cash(1.51B)(55M)(346M)(208M)269M
Free Cash Flow3.76B7.24B6.57B7.28B8.67B

AstraZeneca PLC

NYSE:AZN

Intrinsic Alpha fair value

Locked

Current Price

$178.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.